drugset
drugset / Trial / NCT01165502

Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

NCT01165502 ↗

Phase 1 Completed 40 enrolled CellMed AG, a subsidiary of BTG plc.
RandomizedParallel-groupTriple-blindBasic science

Summary

The primary objective is to assess the safety and tolerability of the GLP-1 peptide analogue CM3.1-AC100 after repeated subcutaneous (sc) doses.

Timeline

Start
2010-07
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CM3.1-AC100 Peptide — Subcutaneous

Indications

No indication recorded.